[1] REDDY M A,TAK PARK J,NATARAJAN R.Epigenetic modifications in the pathogenesis of diabetic nephropathy[J].Semin Nephrol,2013,33(4):341-353.
[2] REIDY K, KANG H M, HOSTETTER T, et al.Molecular mechanisms of diabetic kidney disease[J].J Clin Invest,2014, 124(6):2333-2340.
[3] HA T S,PARK H Y,SEONG S B,et al.Angiotensin II modulates p130 cas of podocytes by the suppression of AMP-activated protein kinase[J]. J Korean Med Sci,2016,31(4):535-541.
[4] LI J J,KWAK S J,JUNG D S,et al.Podocyte biology in diabetic nephropathy[J].Kidney Int Suppl,2007,106(3):S36-S42.
[5] 王颖超,赵宗江,赵敬,等.糖肾平对糖尿病肾病大鼠足细胞nephrin与CD2AP蛋白及其mRNA表达的影响[J].中国中西医结合肾病杂志,2014,15(2):107-109.
[6] JEANSSON M,HARALDSSON B.Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier[J].Am J Physiol Renal Physiol,2006, 15(2):107-109.
[7] RONCONI E,MAZZINGHI B,SAGRINATI C,et al.The role of podocyte damage in the pathogenesis of glomerulosclerosis and possible repair mechanisms[J].G Ital Nefrol,2009,26(6):660-669.
[8] PRICE PM.A role for novel cell-cycle proteins in podocyte biology[J].Kidney Int,2010, 77(8):660-661.
[9] RUSSO G L,RUSSO M,UNGARO P.AMP-activated protein kinase:a target for old drugs against diabetes and cancer[J].Biochem Pharmacol,2013,86(3):339-350.
[10] MOMCILOVIC M,HONG S P,CARLSON M.Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro[J].Biol Chem,2006, 281(35):25336-25343.
[11] LI J J,KWAK S J,JUNG D S,et al.Podocyte biology in diabetic nephropathy[J].Kidney Int Suppl,2007,72(106):S36-S42.
[12] AMADOR-LICONA N,GUÍZAR-MENDOZA J,VARGAS E,et al.The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus[J].Arch Med Res,2000,31(6):571-575.
[13] PIWKOWSKA A, ROGACKA D, AUDZEYENKA I, et al.Combined effect of insulin and high glucose concentration on albumin permeability in cultured rat podocytes[J]. Biochem Biophys Res Commun,2015,461(2): 383-389.
[14] BROSIUS FC, COWARD RJ.Podocytes, signaling pathways, and vascular factors in diabetic kidney disease[J]. Adv Chronic Kidney Dis,2014,21(3): 304-310.
[15] ROGACKA D,PIWKOWSKA A,AUDZEYENKA I,et al.Involvement of the AMPK-PTEN pathway in insulin resistance induced by high glucose in cultured rat podocytes[J].Biochem Cell Biol,2014, 51(8):120-130.
[16] JORGENSEN S B,VIOLLET B,ANDREELLI F,et al.Knockout of the alpha2 but not alphal 5'-AMP- activated protein kinase isoform abolishes 5-amainoimidazole-4-carbxamide-1-beta-4- ribofuranosidebut not contraction-induced glucose uptkae in skeletal muscle[J].Biol Chem,2004,279(2):1070-1079.
[17] OUCHI N,KIHARA S,ARITA Y, et al.Adipocyte-derivedplasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in humanmonocyte-derived macrophages[J].Circulation, 2001,103(8):1057-1063.
[18] WEYER C,FUNAHASHI T,TANAKA S,et al.Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia[J].Clin Endocrinol Metab,2001, 86(5):1930-1935.
[19] LJUBIC S,JAZBEC A,TOMIC M,et al.Inverse levelsof adiponectin in type 1 and type 2 diabetes are in accordance with the state of albuminuria[J]. Int J Endocrinol,2015:372796.
[20] SHARMA K,RAMACHANDRARAO S,QIU G,et al.Adiponectin regulates albuminuria and podocyte function in mice[J].J Clin Invest,2008,118(5):1645-1656.
[21] YAMAUCHI T, KAMON J, MINOKOSHI Y,et al.Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase[J]. Nat Med,2002,8(11):1288-1295.
[22] LIANG F,KUME S,KOYA D.SIRT1 and insulin resistancet[J].Nat Rev Endocrinol,2009,5(7): 367-373.
[23] XIE J,ZHANG X,ZHANG L.Negative regulation of inflammation by SIRT1[J].Pharmacol Res, 2013,67(1): 60-67.
[24] LIU R,ZHONG Y,LI X,et al.Role of transcription factor acetylation in diabetic kidney disease[J]. Diabetes, 2014,63(7):2440-2453.
[25] CANTO C,GERHART-HINES Z,FEIGE JN,et al.AMPK regu-lates energy expenditure by modulating NAD+ metabolism and SIRT1 activity[J].Nature,2009,458(7241):1056-1060.
[26] BROSIUS F C,COWARD R J.Podocytes, signaling pathways, and vascular factors in diabetic kidney disease[J].Adv Chronic Kidney Dis,2014,21(3):304-310.
[27] BERA A,DAS F,GHOSH-CHOUDHURY N,et al.Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion[J].Am Physiol Cell Physiol, 2017, 313(4):C430-C447.
[28] TU Y,GU L,CHEN D,et al.Rhein inhibits autophagy in rat renal tubular cells by regulation of AMPK/mTOR signaling[J].Sci Rep,2017,7:43790.
[29] EID A A,FORD B M,BHANDARY B,et al.Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury[J]. Diabetes,2013,62(8):2935-2947.
[30] GÖDEL M,HARTLEBEN B,HERBACH N,et al.Role of mTOR in podocyte function and diabetic nephropathy in human and mice[J].Clin invest,2011,121(6): 2197-2209.
[31] LEE C H,INOKI K,KARBOWNICZEK M,et al.Constitutive mTOR activation in TSC mutants sensitizes cells to energy
[32] starvation andgenomic damage via p53[J].EMBO,2007,26(6):4812-4823.
[33] 刘淑萍. 黄连素调控AMPK-mTOR信号通路改善高糖诱导的足细胞损伤[D].长春:吉林大学,2016.
[34] 隆敏摇,郑宏庭.抗氧化的NRF2通路与糖尿病及其慢性并发症[J].中华内分泌代谢杂志,2017,33(3):185-189.
[35] GUO H,WANG Y, ZHANG X,et al.Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy[J]. Sci Rep,2017,7(1):6852.
[36] GAUT J P,HOSHI M,JAIN S,et al.Claudin 1 and nephrin label cellular crescents in diabetic glomerulosclerosis[J]. Hum Pathol,2014,45(3):628-635.
[37] SCHNABEL E,ANDERSON J M,FARQUHAR M G.The tight junction protein ZO-1 is concentrated along slit diaphragms of the glomerular epithelium[J].Cell Biol,1990,111(3):1255-1263.
[38] 邹敏书,余健,聂国明,等.1,25-(OH)2D3对糖尿病大鼠ZO-1表达的影响[J].解放军药学学报,2008,24(1):26-28.
[39] 胡光华,刘治民,焦波,等.α-Actinin-4在足细胞脱落机制中的作用[J].临床医药文献杂志,2015,2(33):6947-6948.
[40] 王颖超,于眉,杨敏,等.糖肾平对糖尿病肾病大鼠α-actinin-4表达及足细胞数目影响[J].辽宁中医药大学学报,2018,20(4):31-35. |
